These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36959702)

  • 1. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo design of a tumor-penetrating peptide.
    Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
    Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
    Cho HJ; Park SJ; Lee YS; Kim S
    J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer therapy with iRGD as a tumor-penetrating peptide.
    Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
    Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-penetrating peptides.
    Teesalu T; Sugahara KN; Ruoslahti E
    Front Oncol; 2013; 3():216. PubMed ID: 23986882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
    Zuo H
    J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
    Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
    Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
    Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
    Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery.
    Kang S; Lee S; Park S
    Polymers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
    Lingasamy P; Laarmann AH; Teesalu T
    Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.
    Singh T; Kim TW; Murthy ASN; Paul M; Sepay N; Jeong Kong H; Sung Ryu J; Rim Koo N; Yoon S; Song KH; Jun Baek M; Jeon S; Im J
    Eur J Med Chem; 2024 Feb; 265():116050. PubMed ID: 38128233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles.
    Li C; Chen Z; Zheng D; Zhao J; Lei J
    ACS Appl Bio Mater; 2021 Feb; 4(2):1499-1507. PubMed ID: 35014499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
    Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.